News and Announcements
Shivom Extends its Presale Until Friday April 27th, 2018!
- Published April 25, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom extends presale to April 27th, 2018, 6 PM GMT
- Shivom receiving overwhelming response for currently presale
- Main crowdsale commences on May 3rd, 2018
Shivom in its bid to help registered users to complete their KYC has extended their Presale for another 2 days! This means you can still sign up for the OmiX Token presale until Friday, April 27th, 2018, 6 PM GMT. The bonus will remain consistently at 3% through the remaining days.
The decision to extend the Presale was taken due to the overwhelming response we have received thus far. Due to the backlog of KYC applications, we are allowing users a few more days to participate, before the main crowdsale commences on May 3rd, 2018. Please note that the crowdsale will not carry any bonuses.
If your KYC application is still incomplete, we recommend you complete it before the main public sale begins.
This also means that the Token Presale is still open for those who haven’t registered yet if you still wish to do so and benefit from the early bird bonuses. Become part of the Shivom’s future-changing project by simply signing up at https://shivom.io/.
Thank you for supporting Shivom in the future of genomic information storage and DNA sequencing. Your participation is vital to our vision and will help empower the next era of global healthcare.
Remember the Presale will end on April 27th, 2018 | 6 PM GMT
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
